Synaptogenix, Inc., yon konpayi biopharmaceutique nan etap klinik devlope terapetik rejeneratif pou maladi neurodegenerative, jodi a te anonse plan yo devlope Bryostatin-1 pou tretman paralezi miltip, yon twazyèm endikasyon pou kandida dwòg la. Konpayi an pral kolabore ak Cleveland Clinic atravè yon nouvo akò konsiltasyon.
“Synaptogenix kontan anpil pou l travay avèk ekip ekspè entènasyonal sa a. Yon esè klinik konsantre sou tou de sekirite ak efikasite se priyorite nan kolaborasyon an. Avanse plan devlopman klinik nou yo atravè patenarya se te yon konsantre estratejik pandan ane ki sot pase a epi yo pral kontinye yon konsantre kle pou pi devan. Nou trè kontan ke nou te kapab fè patenarya ak enstitisyon dirijan nan mond lan sou efò tankou kolaborasyon sa a ak Cleveland Clinic for MS ak patenarya Fragile X nou te anonse deja ak Nemours AI Dupont,” te deklare Dr Alan Tuchman, CEO nan Synaptogenix, Inc.
"Sklewoz miltip ansanm ak maladi alzayme a ("AD") ak sendwòm X frajil kòm twazyèm endikasyon nou an ak potansyèl benefis klinik nan Bryostatin-1. Eliminasyon sinaps nan pasyan MS, tankou moun ki pèdi nan AD, pa te adrese pa estrateji dwòg ki disponib kounye a. Atravè sinaptojèn, mekanis restorasyon aksyon li yo, nou kwè ke Bryostatin-1 se yon pozisyon inik pou vize pèt sinaptik ak malfonksyònman mantal nan MS, ak potansyèlman lòt aspè nan maladi a tankou enflamasyon ak demyelination. Nou pral travay avèk Klinik Cleveland pou finalize yon pwotokòl pi vit posib ak objektif pou nou avanse nan yon esè klinik touswit apre sa,” te deklare Doktè Daniel Alkon, Prezidan ak Direktè Syantifik Konpayi an.
KISA POU RETIRE NAN ATIK SA A:
- We will work with the Cleveland Clinic to finalize a protocol as soon as possible with the goal of moving towards a clinical trial soon thereafter,”.
- We are very pleased that we’ve been able to partner with world leading institutions on endeavors such as this collaboration with Cleveland Clinic for MS and our previously announced Fragile X partnership with Nemours A.
- Through its synaptogenic, restorative mechanisms of action, we believe that Bryostatin-1 is uniquely positioned to target synaptic loss and cognitive dysfunction in MS, and potentially other aspects of the disease such as inflammation and demyelination.
